AIM ImmunoTech Inc (AIM)
0.2611
0.00 (0.00%)
USD |
NYAM |
Nov 01, 16:00
0.25
-0.01
(-4.25%)
After-Hours: 20:00
AIM ImmunoTech Enterprise Value: 9.109M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 9.109M |
| October 31, 2024 | 9.033M |
| October 30, 2024 | 8.596M |
| October 29, 2024 | 9.673M |
| October 28, 2024 | 9.673M |
| October 25, 2024 | 9.489M |
| October 24, 2024 | 9.071M |
| October 23, 2024 | 9.033M |
| October 22, 2024 | 9.610M |
| October 21, 2024 | 9.350M |
| October 18, 2024 | 8.432M |
| October 17, 2024 | 8.976M |
| October 16, 2024 | 9.033M |
| October 15, 2024 | 8.850M |
| October 14, 2024 | 8.976M |
| October 11, 2024 | 9.420M |
| October 10, 2024 | 9.223M |
| October 09, 2024 | 8.913M |
| October 08, 2024 | 9.166M |
| October 07, 2024 | 9.603M |
| October 04, 2024 | 9.261M |
| October 03, 2024 | 7.900M |
| October 02, 2024 | 8.090M |
| October 01, 2024 | 8.723M |
| September 30, 2024 | 8.416M |
| Date | Value |
|---|---|
| September 27, 2024 | 8.574M |
| September 26, 2024 | 8.003M |
| September 25, 2024 | 6.460M |
| September 24, 2024 | 7.666M |
| September 23, 2024 | 7.014M |
| September 20, 2024 | 7.843M |
| September 19, 2024 | 9.203M |
| September 18, 2024 | 9.620M |
| September 17, 2024 | 10.35M |
| September 16, 2024 | 9.546M |
| September 13, 2024 | 9.540M |
| September 12, 2024 | 9.717M |
| September 11, 2024 | 10.28M |
| September 10, 2024 | 11.14M |
| September 09, 2024 | 11.49M |
| September 06, 2024 | 11.32M |
| September 05, 2024 | 11.49M |
| September 04, 2024 | 11.99M |
| September 03, 2024 | 12.46M |
| August 30, 2024 | 12.19M |
| August 29, 2024 | 13.14M |
| August 28, 2024 | 12.86M |
| August 27, 2024 | 13.51M |
| August 26, 2024 | 13.92M |
| August 23, 2024 | 13.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-21.35M
Minimum
Dec 29 2022
152.07M
Maximum
Mar 09 2020
18.96M
Average
8.723M
Median
Oct 01 2024
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 524.04M |
| Protalix BioTherapeutics Inc | 67.32M |
| Electromed Inc | 181.75M |
| Xtant Medical Holdings Inc | 102.06M |
| Armata Pharmaceuticals Inc | 170.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.836M |
| Revenue (Quarterly) | 0.05M |
| Total Expenses (Quarterly) | 3.744M |
| EPS Diluted (Quarterly) | -0.03 |
| Gross Profit Margin (Quarterly) | 84.00% |
| Profit Margin (Quarterly) | -3.67K% |
| Earnings Yield | -218.3% |
| Normalized Earnings Yield | -214.68 |